In the following video, Motley Fool health care bureau chief Brenton Flynn continues his look at Intuitive Surgical's (ISRG +0.41%) annual report. Specifically, he takes a look at one possible new competitive threat emerging on the company's radar. The company, called IMRIS, has its primary focus on intraoperative MRI technology, but is currently conducting clinical trials for a surgical platform targeting neurological conditions. Brenton tells investors whether this company is a concern and what other competitive threats Intuitive might be facing.
